At the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma. Jean-Francois Korobelnik, MD, ...
María Berrocal, MD, titled her Kreissig Award Lecture "Throwing away wisdom: How we abandon what works." María Berrocal, from Drs. Berrocal and Associates in San Juan, Puerto Rico, delivered the ...
The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.” Data from Opthea ...
The funding will support activities like formal pharmacology and toxicology testing. RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of ...
The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD. Chengdu Origen Biotechnology Co, Ltd. And Vanotech Ltd. recently announced the dosing of the first ...
Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...
Miguel A. Quiroz-Reyes, MD, PhD, and colleagues found that cigarette smoking negatively affects the choroidal vascularity, as indicated by a significant reduction of the choroidal vascularity index ...
The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1). In December 2024, a ...
A panelist discusses how a woman aged 77 years with bilateral neovascular age-related macular degeneration (nAMD) demonstrated different responses to treatments between her eyes, showing a superior ...
ENCELTO is the first and only FDA-approved treatment for MacTel. The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals for the ...
Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients. Following the FDA approval of ranibizumab-hkdz (Ranluspec; ...
The designation is based off previously reported phase 3 data from the ongoing DRAGON trial. Belite Bio recently announced the US Food and Drug Administration (FDA) granted Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results